Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. 8-K earnings release, 10-K stay in one workspace.
ATOS
$2.44
+0.83%
ATOS
· Atossa Therapeutics, Inc.
$2.44
+0.02 (+0.83%)
At close · Oct 9
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt as to the Company's ability to continue as a going concern. The accompanying Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to continue as a going concern.”View the 10-Q filed Aug 7, 2026
Market Cap
$25.24M
Shares
9.98M
Volume · Oct 9
259.43K
Avg daily vol (3M)
64.82K
All webcasts
Earnings call · FY2024 Q4
Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Net income · derived Q4
-$6.35M
Research materials
Open the source you need; every reader stays inside this workspace.
SEC filing · Item 2.02
8-K earnings release
Filed Mar 25, 2025 · complete as-filed document
SEC periodic report
10-K report
Filed Mar 25, 2025 · complete as-filed document